高级检索
刘银凤, 袁关利, 刘佳妮, 韩猛, 吕骥, 吴梓政. 趋化因子配体13在三阴性乳腺癌中的表达及临床意义[J]. 实用临床医药杂志, 2022, 26(18): 57-62. DOI: 10.7619/jcmp.20221448
引用本文: 刘银凤, 袁关利, 刘佳妮, 韩猛, 吕骥, 吴梓政. 趋化因子配体13在三阴性乳腺癌中的表达及临床意义[J]. 实用临床医药杂志, 2022, 26(18): 57-62. DOI: 10.7619/jcmp.20221448
shu
LIU Yinfeng, YUAN Guanli, LIU Jiani, HAN Meng, LYU Ji, WU Zizheng. Expression and clinical significance of CXC motif chemokine ligand 13 in triple-negative breast cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(18): 57-62. DOI: 10.7619/jcmp.20221448
Citation: LIU Yinfeng, YUAN Guanli, LIU Jiani, HAN Meng, LYU Ji, WU Zizheng. Expression and clinical significance of CXC motif chemokine ligand 13 in triple-negative breast cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(18): 57-62. DOI: 10.7619/jcmp.20221448
shu

趋化因子配体13在三阴性乳腺癌中的表达及临床意义

Expression and clinical significance of CXC motif chemokine ligand 13 in triple-negative breast cancer

    摘要
  • 摘要:
    目的 探讨趋化因子配体13(CXCL13)表达水平对三阴性乳腺癌(TNBC)患者总体生存期(OS)的影响，分析CXCL13与肿瘤浸润性淋巴细胞(TIL)浸润程度及常见免疫检查点表达的关系。
    方法 下载癌症基因组图谱数据库中TNBC患者的转录组测序结果及临床资料数据，分析CXCL13表达与TNBC患者OS的关系。应用基因集富集分析(GSEA)软件挖掘CXCL13在TNBC中的生物学功能; 应用肿瘤免疫评估资源(TIMER)数据库分析CXCL13与TNBC中TIL浸润程度及常见免疫检查点表达量的相关性。
    结果 CXCL13在TNBC中呈显著高表达(P < 0.001)，其表达量与患者OS具有显著相关性(P < 0.05)。GSEA结果显示, CXCL13在TNBC中高表达可使关键免疫相关通路活化。TIMER数据库分析显示, CXCL13与TNBC中TIL的浸润程度及常见免疫检查点程序性死亡受体1、程序性死亡受体-配体1及细胞毒性T淋巴细胞相关蛋白4的表达量呈显著正相关(P < 0.001)。
    结论 CXCL13是TNBC患者预后的预测因子，或可在TNBC的免疫治疗中发挥重要作用。

     

    Abstract:
    Objective To explore the effect of the expression level of CXC motif chemokine ligand 13 (CXCL13) on the overall survival (OS) of patients with triple-negative breast cancer (TNBC), and to analyze the relationships of CXCL13 with infiltration degree of tumor-infiltrating lymphocytes (TIL) and the expression of common immune checkpoints.
    Methods The transcriptome sequencing results and clinical data of TNBC patients in the cancer Genome Atlas database were downloaded, and the relationship between CXCL13 expression and OS in TNBC patients was analyzed. The biological function of CXCL13 in TNBC was excavated by Gene-set Enrichment Analysis (GSEA); the Tumor Immune Estimation Resource (TIMER) database was used to analyze the correlations of the expression level of CXCL13 with TIL infiltration degree and the expression of common immune checkpoints in TNBC.
    Results CXCL13 was significantly highly expressed in TNBC (P < 0.001), and its expression level was significantly correlated with OS of patients (P < 0.05). Results of GSEA showed that the high expression of CXCL13 in TNBC was able to activate key immune-related pathways. TIMER database analysis showed that CXCL13 was significantly positively correlated with the infiltration degree of TIL and the expressions of common immune checkpoints such as programmed death receptor 1, programmed death receptor ligand 1 and cytotoxic T lymphocyte associated protein 4 at in TNBC patients (P < 0.001).
    Conclusion CXCL13 is a prognostic factor for patients with TNBC, and may play an important role in immunotherapy of TNBC.

     

    • HTML全文
    • 参考文献(19)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回